From the Journals

Metformin and AMD: Signal or Noise?

Five-year population study details 37% lower incidence of intermediate AMD in type 2 diabetic patients prescribed metformin

Share

A study linked metformin use to a 37% lower incidence of intermediate age-related macular degeneration (AMD) over five years in type 2 diabetes patients. Conducted under the ISDR program in Liverpool, UK, this population-based research utilized systematic retinal image grading instead of administrative data, enhancing its reliability. Although baseline data showed varying AMD stages, metformin did not affect early AMD progression. Findings suggest metformin's potential benefits beyond glycemic control, warranting further clinical trials, despite observational limitations.

Original Source(s)

Metformin and AMD: Signal or Noise?

Five-year population study details 37% lower incidence of intermediate AMD in type 2 diabetic patients prescribed metformin

  • by Conexiant News Staff

  • February 16, 2026

  • 4 min

Related Content

Coding Q&A: Coding Guidelines for Wet AMD

Proper use of ICD-10-CM codes ensures compliance and prompt payment.

A Solution for Irregular Astigmatism Pre-Cataract Surgery

PentaVision is an independent company dedicated to eye care professionals. More about our magazines, newsletters, conferences, education and other services at pentavisionmedia.com.

  • November 1, 2020

  • 8 min
Integration of Vision Services Remains an Unmet Need in FQHCs

Telemedicine, funding, and provider partnerships can help, researchers say.